Pluri (NASDAQ:PLUR) Posts Quarterly Earnings Results

Pluri (NASDAQ:PLURGet Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.34 million during the quarter.

Pluri Trading Down 8.8%

Pluri stock opened at $1.25 on Friday. The stock has a market cap of $13.94 million, a price-to-earnings ratio of -0.28 and a beta of 0.68. The company’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $2.52. Pluri has a 52 week low of $1.24 and a 52 week high of $5.17.

Institutional Trading of Pluri

A hedge fund recently bought a new position in Pluri stock. Jane Street Group LLC acquired a new stake in shares of Pluri Inc. (NASDAQ:PLURFree Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Report on Pluri

About Pluri

(Get Free Report)

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.

Recommended Stories

Earnings History for Pluri (NASDAQ:PLUR)

Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.